FDA Approved: ARCALYST — Supplemental Application (Kiniksa Pharmaceuticals (UK), Ltd.)

View source ↗

Summary

The FDA approved a supplemental application for ARCALYST (rilonacept) by Kiniksa Pharmaceuticals (UK), Ltd., updating the existing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Pericarditis

Drugs mentioned

• Arcalyst (rilonacept)

Snippet

SUPPL AP for ARCALYST (RILONACEPT)